Chlormadinone caproate
![]() | |
Clinical data | |
---|---|
Other names | CMC; Chlormadinone hexanoate; 6-Chloro-17α-hydroxy-Δ6-progesterone hexanoate; 6-Chloro-17α-hydroxypregna-4,6-diene-3,20-dione hexanoate |
Routes of administration | Intramuscular injection |
Drug class | Progestogen; Progestin; Progestogen ester |
Identifiers | |
| |
CAS Number | |
UNII | |
Chemical and physical data | |
Formula | C27H37ClO4 |
Molar mass | 461.04 g·mol−1 |
3D model (JSmol) | |
| |
|
Chlormadinone caproate (CMC) is a progestin and a progestogen ester which was studied for potential use in combined injectable contraceptives but was never marketed.[1][2][3][4] It was assessed in combination with estradiol valerate at doses of 80 mg and 3 mg, respectively.[1][2][3] In addition to chlormadinone acetate (CMA), analogues of CMC include gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, megestrol caproate, and methenmadinone caproate.[5]
See also
[edit]References
[edit]- ^ a b Daniel R. Mishell (1983). Long-acting Steroid Contraception. Raven Press. pp. 69, 77. ISBN 978-0-89004-932-7.
- ^ a b Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
- ^ a b Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore). 4 (Suppl 1): S1–34. doi:10.3109/01443619409027641. PMID 12290848.
- ^ Bopp RJ, Murphy HW, Nash JF, Novotny CR (September 1972). "GLC determination of chlormadinone acetate in plasma". J Pharm Sci. 61 (9): 1441–4. doi:10.1002/jps.2600610919. PMID 4115914.
- ^ Bouchard, P. (2005). "Chlormadinone acetate (CMA) in oral contraception--a new opportunity". The European Journal of Contraception & Reproductive Health Care. 10 (Suppl 1): 7–11. doi:10.1080/13625180500434889. ISSN 1362-5187. PMID 16356876. S2CID 22898956.